See more : GQG Partners Inc. (GQG.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Bruker Corporation (BRKR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bruker Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- G5 Entertainment AB (publ) (0QUS.L) Income Statement Analysis – Financial Results
- RTX Corporation (RTX) Income Statement Analysis – Financial Results
- Pop Mart International Group Limited (9992.HK) Income Statement Analysis – Financial Results
- Terranet AB (TERRNT-B.ST) Income Statement Analysis – Financial Results
- Eupraxia Pharmaceuticals Inc. (EPRX) Income Statement Analysis – Financial Results
Bruker Corporation (BRKR)
About Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.96B | 2.53B | 2.42B | 1.99B | 2.07B | 1.90B | 1.77B | 1.61B | 1.62B | 1.81B | 1.84B | 1.79B | 1.65B | 1.30B | 1.11B | 1.11B | 547.58M | 435.83M | 297.57M | 284.42M | 260.68M | 116.37M | 92.69M | 76.60M | 64.69M | 42.21M |
Cost of Revenue | 1.45B | 1.23B | 1.21B | 1.05B | 1.08B | 995.60M | 952.90M | 868.80M | 915.20M | 1.05B | 1.03B | 960.00M | 899.20M | 698.90M | 595.90M | 602.10M | 294.44M | 236.50M | 171.76M | 165.94M | 144.83M | 55.87M | 43.59M | 35.59M | 28.13M | 0.00 |
Gross Profit | 1.51B | 1.31B | 1.21B | 939.80M | 995.30M | 900.00M | 813.00M | 742.50M | 708.60M | 763.30M | 805.20M | 831.40M | 752.50M | 606.00M | 518.60M | 505.00M | 253.14M | 199.33M | 125.81M | 118.48M | 115.85M | 60.50M | 49.10M | 41.02M | 36.56M | 42.21M |
Gross Profit Ratio | 51.05% | 51.59% | 50.03% | 47.29% | 48.02% | 47.48% | 46.04% | 46.08% | 43.64% | 42.20% | 43.78% | 46.41% | 45.56% | 46.44% | 46.53% | 45.61% | 46.23% | 45.74% | 42.28% | 41.66% | 44.44% | 51.99% | 52.97% | 53.54% | 56.51% | 100.00% |
Research & Development | 294.80M | 235.90M | 220.80M | 198.00M | 187.70M | 173.40M | 162.70M | 149.00M | 145.70M | 174.20M | 190.50M | 195.30M | 177.20M | 141.40M | 126.40M | 133.80M | 58.47M | 49.96M | 41.36M | 43.22M | 38.03M | 20.73M | 18.47M | 20.03M | 15.14M | 0.00 |
General & Administrative | 730.10M | 610.80M | 564.50M | 477.80M | 500.20M | 444.70M | 415.90M | 390.50M | 392.20M | 451.00M | 437.90M | 442.40M | 406.60M | 303.10M | 69.50M | 254.50M | 140.04M | 112.99M | 73.81M | 76.38M | 77.76M | 33.82M | 27.72M | 20.25M | 14.76M | 0.00 |
Selling & Marketing | 0.00 | -3.40M | -3.30M | -9.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00M | -5.80M | 185.80M | 183.80M | 105.98M | 84.01M | 51.44M | 55.98M | 60.42M | 26.81M | 21.71M | 0.00 | 0.00 | 0.00 |
SG&A | 730.10M | 607.40M | 561.20M | 468.60M | 500.20M | 444.70M | 415.90M | 390.50M | 392.20M | 451.00M | 437.90M | 442.40M | 403.60M | 297.30M | 255.30M | 254.50M | 140.04M | 112.99M | 73.81M | 76.38M | 77.76M | 33.82M | 27.72M | 20.25M | 14.76M | 0.00 |
Other Expenses | 52.20M | -29.70M | -14.30M | -24.90M | -6.50M | -19.50M | -19.70M | -25.80M | -20.40M | -21.20M | -28.60M | -13.90M | 13.10M | 5.80M | 200.00K | 8.50M | 4.66M | 5.72M | 0.00 | 0.00 | 9.75M | 202.00K | -356.00K | 0.00 | 3.49M | 42.37M |
Operating Expenses | 1.08B | 843.30M | 782.00M | 666.60M | 687.90M | 618.10M | 578.60M | 539.50M | 537.90M | 625.20M | 628.40M | 637.70M | 596.90M | 450.30M | 255.30M | 388.30M | 198.51M | 162.95M | 115.17M | 119.59M | 125.53M | 54.75M | 45.83M | 40.28M | 33.38M | 42.37M |
Cost & Expenses | 2.53B | 2.07B | 1.99B | 1.71B | 1.77B | 1.61B | 1.53B | 1.41B | 1.45B | 1.67B | 1.66B | 1.60B | 1.50B | 1.15B | 851.20M | 990.40M | 492.95M | 399.45M | 286.93M | 285.53M | 270.36M | 110.62M | 89.42M | 75.87M | 61.51M | 42.37M |
Interest Income | 11.20M | 4.10M | 900.00K | 3.20M | 1.30M | 1.20M | 800.00K | 300.00K | 1.20M | 800.00K | 1.00M | 900.00K | 1.00M | 900.00K | 1.00M | 4.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 16.40M | 16.10M | 14.30M | 14.40M | 16.00M | 12.60M | 15.40M | 13.20M | 13.00M | 13.30M | 13.40M | 14.30M | 7.30M | 5.60M | 7.50M | 40.50M | 11.84M | 3.96M | 0.00 | 3.85M | 6.36M | 20.15M | 0.00 | 0.00 | 1.35M | 0.00 |
Depreciation & Amortization | 114.90M | 88.80M | 89.20M | 80.50M | 75.60M | 64.90M | 63.90M | 54.30M | 53.30M | 59.70M | 61.30M | 59.10M | 3.00M | 5.80M | 29.70M | 29.90M | 12.63M | 13.29M | 8.61M | 9.79M | 16.87M | 8.20M | 6.04M | 4.15M | 3.49M | 0.00 |
EBITDA | 599.00M | 545.30M | 497.10M | 320.70M | 380.00M | 340.10M | 299.50M | 262.10M | 235.90M | 215.60M | 239.10M | 211.70M | 205.70M | 155.70M | 166.30M | 134.80M | 63.07M | 49.87M | 19.25M | 8.68M | 697.00K | 17.47M | 10.30M | 4.88M | 6.66M | -161.00K |
EBITDA Ratio | 20.21% | 21.75% | 21.37% | 17.79% | 18.48% | 18.29% | 16.89% | 15.97% | 14.08% | 11.57% | 12.94% | 12.14% | 9.60% | 12.38% | 35.67% | 14.75% | 13.29% | 11.85% | 6.47% | 3.05% | 5.91% | 20.80% | 9.68% | 6.64% | 10.93% | -0.38% |
Operating Income | 436.90M | 432.70M | 413.30M | 248.30M | 300.90M | 262.40M | 214.70M | 177.20M | 145.70M | 105.40M | 148.20M | 156.00M | 155.60M | 155.70M | 136.70M | 108.20M | 49.97M | 30.66M | 10.64M | -1.12M | -9.68M | 5.75M | 3.27M | 734.00K | 3.18M | -161.00K |
Operating Income Ratio | 14.74% | 17.10% | 17.09% | 12.49% | 14.52% | 13.84% | 12.16% | 11.00% | 8.97% | 5.83% | 8.06% | 8.71% | 9.42% | 11.93% | 12.27% | 9.77% | 9.13% | 7.04% | 3.57% | -0.39% | -3.71% | 4.94% | 3.53% | 0.96% | 4.91% | -0.38% |
Total Other Income/Expenses | 107.30M | -18.80M | -19.70M | -22.50M | -20.50M | -17.70M | -21.70M | -4.20M | -17.70M | -4.10M | -23.60M | -17.70M | -10.10M | -5.60M | -7.60M | -15.00M | -89.09M | 3.76M | -780.00K | -3.78M | 1.85M | -9.88M | 2.73M | 1.59M | -1.32M | 161.00K |
Income Before Tax | 544.20M | 413.90M | 393.60M | 225.80M | 280.40M | 244.70M | 197.80M | 177.60M | 128.00M | 101.30M | 124.60M | 138.30M | 145.50M | 150.10M | 129.10M | 93.20M | 48.61M | 34.42M | 11.95M | -4.90M | -7.83M | -4.14M | 6.01M | 2.32M | 1.86M | 0.00 |
Income Before Tax Ratio | 18.36% | 16.36% | 16.28% | 11.36% | 13.53% | 12.91% | 11.20% | 11.02% | 7.88% | 5.60% | 6.77% | 7.72% | 8.81% | 11.50% | 11.58% | 8.42% | 8.88% | 7.90% | 4.02% | -1.72% | -3.00% | -3.56% | 6.48% | 3.03% | 2.88% | 0.00% |
Income Tax Expense | 117.70M | 116.40M | 113.00M | 64.40M | 82.40M | 63.70M | 117.50M | 23.10M | 23.10M | 41.70M | 42.80M | 60.10M | 51.50M | 53.30M | 48.10M | 28.00M | 16.78M | 15.93M | 8.26M | 2.87M | 9.72M | 2.06M | 2.37M | 254.00K | 986.89K | 0.00 |
Net Income | 427.20M | 296.60M | 277.10M | 157.80M | 197.20M | 179.70M | 78.60M | 153.60M | 101.60M | 56.70M | 80.10M | 77.50M | 92.30M | 95.40M | 81.20M | 64.90M | 31.53M | 18.48M | 3.65M | -7.83M | -17.55M | -6.20M | 3.64M | 2.25M | 1.25M | 0.00 |
Net Income Ratio | 14.41% | 11.72% | 11.46% | 7.94% | 9.51% | 9.48% | 4.45% | 9.53% | 6.26% | 3.13% | 4.35% | 4.33% | 5.59% | 7.31% | 7.29% | 5.86% | 5.76% | 4.24% | 1.23% | -2.75% | -6.73% | -5.33% | 3.92% | 2.94% | 1.93% | 0.00% |
EPS | 2.92 | 2.00 | 1.83 | 1.03 | 1.27 | 1.15 | 0.50 | 0.95 | 0.60 | 0.34 | 0.48 | 0.47 | 0.56 | 0.58 | 0.50 | 0.40 | 0.61 | 0.18 | 0.10 | -0.08 | -0.17 | -0.12 | -0.05 | 0.04 | 0.03 | 0.00 |
EPS Diluted | 2.90 | 1.99 | 1.81 | 1.02 | 1.26 | 1.14 | 0.49 | 0.95 | 0.60 | 0.33 | 0.48 | 0.46 | 0.55 | 0.58 | 0.49 | 0.39 | 0.60 | 0.18 | 0.10 | -0.08 | -0.17 | -0.12 | -0.05 | 0.04 | 0.03 | 0.00 |
Weighted Avg Shares Out | 146.40M | 148.60M | 151.40M | 153.40M | 155.20M | 156.20M | 158.10M | 161.40M | 168.20M | 167.80M | 166.50M | 166.00M | 165.40M | 164.40M | 163.50M | 162.70M | 161.20M | 101.51M | 100.82M | 96.38M | 103.26M | 52.60M | 54.06M | 56.25M | 45.50M | 45.50M |
Weighted Avg Shares Out (Dil) | 147.20M | 149.40M | 152.90M | 154.60M | 156.60M | 157.20M | 159.10M | 162.20M | 169.10M | 169.50M | 168.50M | 167.40M | 166.90M | 165.70M | 164.90M | 165.60M | 164.30M | 102.56M | 101.13M | 96.38M | 103.26M | 52.60M | 54.06M | 56.25M | 45.50M | 45.50M |
Why Is Bruker (BRKR) Up 0.9% Since Last Earnings Report?
Bruker Stock Might Rise From the Launch of Dimension Nexus AFM
Bruker Introduces Dimension Nexus™ Atomic Force Microscope
New Strong Sell Stocks for November 21st
New Strong Sell Stocks for November 12th
Bruker Corporation to Present at Upcoming Investor Conferences
BRKR Stock Declines Despite Launching EpicIF Technology for CellScape
Bruker Announces EpicIFTM, Revolutionary Fluorescence Signal Removal Technology, Transforming CellScape Spatial Proteomics Platform
BRKR Misses on Q3 Earnings, Cuts '24 View, Stock Up in Aftermarket
Bruker Corporation (BRKR) Q3 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports